February 13, 2017

BC Platforms joins fight against cancer

BC Platforms will link clinical and genomic data from the hospital’s tumour biobank to enable statistical analysis.
BC Platforms will link clinical and genomic data from the hospital’s tumour biobank to enable statistical analysis.
istock.com/Reptile8488

BC Platforms, a provider of genomic data management solutions, has partnered with Dartmouth-Hitchcock Hospital in the United States.

The deal was signed with Dartmouth-Hitchcock Medical Center’s laboratory of Clinical Genomics and Advanced Technology in the Department of Pathology & Laboratory Medicine.

BC Platforms will link clinical and genomic data from the hospital’s tumour biobank to enable statistical analysis of the patient population via the BC|GENOME toolset. The company will also offer BC|PREDICT, which facilitates the elucidation of disease-related genes from next generation sequencing data.

The deal aims to provide information for translational research to transform the way that cancer is treated.

“We are delighted to be working in partnership with Dartmouth-Hitchcock to support translational research initiatives in cancer,” Tero Silvola, CEO at BC Platforms, tells. “Together we will explore the use of BC Platforms tertiary analysis tools for individual cancer patients but also explore the function of large batch automated analysis to establish common denominators in disease progression.”

BC Platforms currently delivers solutions to over 50 leading international institutions in 18 countries.

Looking for more good news? Subscribe to our newsletter

Share: